Health Resources and Services Administration, HHS.
In compliance with the requirement for opportunity for public comment on proposed data collection projects (Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995), the Health Resources and Services Administration (HRSA) announces plans to submit an Information Collection Request (ICR), described below, to the Office of Management and Budget (OMB). Prior to submitting the ICR to OMB, HRSA seeks comments from the public regarding the burden estimate, below, or any other aspect of the ICR.
Comments on this Information Collection Request must be received no later than December 21, 2015.
Submit your comments to email@example.com or mail the HRSA Information Collection Clearance Officer, Room 10-29, Parklawn Building, 5600 Fishers Lane, Rockville, MD 20857.
Start Further Info
FOR FURTHER INFORMATION CONTACT:
To request more information on the proposed project or to obtain a copy of the data collection plans and draft instruments, email firstname.lastname@example.org or call the HRSA Information Collection Clearance Officer at (301) 443-1984.
End Further Info
Start Supplemental Information
When submitting comments or requesting information, please include the information request collection title for reference.
Information Collection Request Title: Enrollment and Re-Certification of Entities in the 340B Drug Pricing Program and Collection of Manufacturer Data to Verify 340B Drug Pricing Program Ceiling Price Calculations.
OMB No. 0915-0327—Revision.
Abstract: Section 602 of Public Law 102-585, the Veterans Health Care Act of 1992, enacted as Section 340B of the Public Health Service Act (PHS Act; “Limitation on Prices of Drugs Purchased by Covered Entities”), provides that a manufacturer who sells covered outpatient drugs to eligible entities must sign a Pharmaceutical Pricing Agreement (PPA) with the Secretary of Health and Human Services in which the manufacturer agrees to charge a price for covered outpatient drugs that will not exceed an amount determined under a statutory formula (“ceiling price”). A manufacturer subject to a PPA must offer all covered outpatient drugs at no more than the ceiling price to a covered entity listed in the 340B Program database. The manufacturer shall rely on the information in the 340B database to determine if the covered entity is participating in the 340B Program or for any notifications of changes to eligibility that may occur within a quarter. By signing the PPA, the manufacturer agrees to comply with all applicable statutory and regulatory requirements.
The purpose of this revision is to include an addendum to the PPA to incorporate the administrative requirement for manufacturer integrity provisions directly addressed in the Affordable Care Act.
Need and Proposed Use of the Information: HRSA is proposing revisions to the current PPA to include an addendum in response to manufacturer integrity provisions implemented in the Affordable Care Act. Section 7102(b) of the Affordable Care Act amends section 340B(a)(1) of the Public Health Service Act (PHSA) to add two new requirements for inclusion in the PPA with manufacturers of covered outpatient drugs:
I. “Each such agreement shall require that the manufacturer furnish the Secretary with reports, on a quarterly basis, of the price for each covered outpatient drug subject to the agreement that, according to the manufacturer, represents the maximum price that covered entities may permissibly be required to pay for the drug (referred to in this section as the “ceiling price”) and
II. “. . . shall require that the manufacturer offer each covered entity covered outpatient drugs for purchase at or below the applicable ceiling price if such drug is made available to any other purchaser at any price.”
These requirements shall be included in the PPA addendum to be signed by manufacturers participating in the 340B Program to ensure that the provisions of the 340B statute requiring inclusion in the PPA are satisfied. The execution of the addendum by manufacturers will fulfill the administrative requirement of the statute that these provisions be included in the PPA. The burden imposed on manufacturers by the proposed requirement of the PPA is minimal because the addendum does not impose requirements beyond review and a signature by the manufacturer.
Likely Respondents: Drug Manufacturers.
Burden Statement: Burden in this context means the time expended by persons to generate, maintain, retain, disclose or provide the information requested. This includes the time needed to review instructions; to develop, acquire, install and utilize technology and systems for the purpose of collecting, validating and verifying information, processing and maintaining information, and disclosing and providing information; to train personnel and to be able to respond to a collection of information; to search data sources; to complete and review the collection of information; and to transmit or otherwise disclose the information. The total annual burden hours estimated for this Information Collection Request are summarized in the table below.Start Printed Page 63561
Total Estimated Annualized Burden Hours
|Form name||Number of respondents||Number of responses per
respondent||Total responses||Hours per respondent||Total burden hours|
|Hospital Enrollment, Additions & Recertifications|
|340B Program Registrations & Certifications for Hospitals||194||1||194||2||388|
|Certifications to Enroll Hospital Outpatient Facilities||697||8||5576||0.5||2788|
|Hospital Annual Recertifications||2134||6||12804||0.25||3201|
|Registrations and Recertifications for Entities Other Than Hospitals|
|340B Registrations for Community Health Centers||427||3||1281||1||1281|
|340B Registrations for STD/TB Clinics||647||1||647||1||647|
|340B Registrations for Various Other Eligible Entity Types||405||1||405||1||405|
|Community Health Center Annual Recertifications||1204||5||6020||0.25||1505|
|STD & TB Annual Recertifications||3123||1||3123||0.25||780.75|
|Annual Recertification for entities other than Hospitals, Community Health Centers, and STD/TB Clinics||4899||1||4899||0.25||1224.75|
|Contracted Pharmacy Services Registration & Recertifications|
|Contracted Pharmacy Services Registration||1758||5||8790||1||8790|
|Other Information Collections|
|Submission of Administrative Changes for any Covered Entity||9396||1||9396||0.5||4698|
|Submission of Administrative Changes for any Manufacturer||350||1||350||0.5||175|
|Manufacturer Data Required to Verify 340B Ceiling Price Calculations||600||4||2400||0.5||1200|
|Pharmaceutical Pricing Agreement||200||1||200||1||200|
|Pharmaceutical Pricing Agreement (PPA) Addendum||620||1||620||0.5||310|
HRSA specifically requests comments on (1) the necessity and utility of the proposed information collection for the proper performance of the agency's functions, (2) the accuracy of the estimated burden, (3) ways to enhance the quality, utility, and clarity of the information to be collected, and (4) the use of automated collection techniques or other forms of information technology to minimize the information collection burden.
End Supplemental Information
Director, Division of the Executive Secretariat.
[FR Doc. 2015-26522 Filed 10-19-15; 8:45 am]
BILLING CODE 4165-15-P